| Literature DB >> 19584916 |
Kun-Nan Tsai1, Err-Cheng Chan, Tsung-Yeh Tsai, Kuei-Tien Chen, Chun-Yu Chen, Kenneth Hung, Chung-Ming Chen.
Abstract
To unravel the cytotoxic effect of the recombinant CFP-10/ESAT-6 protein (rCFES) on WI-38 cells, an integrative analysis approach, combining time-course microarray data and annotated pathway databases, was proposed with the emphasis on identifying the potentially crucial pathways. The potentially crucial pathways were selected based on a composite criterion characterizing the average significance and topological properties of important genes. The analysis results suggested that the regulatory effect of rCFES was at least involved in cell proliferation, cell motility, cell survival, and metabolisms of WI-38 cells. The survivability of WI-38 cells, in particular, was significantly decreased to 62% with 12.5 microM rCFES. Furthermore, the focal adhesion pathway was identified as the potentially most-crucial pathway and 58 of 65 important genes in this pathway were downregulated by rCFES treatment. Using qRT-PCR, we have confirmed the changes in the expression levels of LAMA4, PIK3R3, BIRC3, and NFKBIA, suggesting that these proteins may play an essential role in the cytotoxic process in the rCFES-treated WI-38 cells.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19584916 PMCID: PMC2702506 DOI: 10.1155/2009/917084
Source DB: PubMed Journal: J Biomed Biotechnol ISSN: 1110-7243
Figure 1SDS-PAGE analysis of the purified rCFES. Lane M: Protein marker; Lane 1: IPTG-induced cell lysate; Lane 2: purified rCFES.
Figure 2Effects of rCFES on WI-38 cell viability, in which the bars indicated the survival rates of WI-38 cells treated with different concentrations of rCFES. The data are expressed as mean values (± standard deviation) of three experiments.
The values of the descriptors constituting the composite score, R, and the selected pathways sorted in the ascending order of R derived by the pathway topology analysis.
| Pathway | Density | Average significance | MD-Cluster | MUD-Cluster | Composite score | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Entry | Name | ||||||||||
| hsa04510 | Focal adhesion | 65 | 0.3351 | 0.2697 | 0.00130 | 0.00000039 | 11 | 0.00177 | 13 | 0.00200 | 46 |
| hsa00450 | Selenoamino acid metabolism | 14 | 0.4118 | 0.5833 | 0.00119 | 0.00000365 | 6 | 0.00195 | 7 | 0.00221 | 49 |
| hsa00230 | Purine metabolism | 54 | 0.3506 | 0.4230 | 0.00501 | 0.00002726 | 44 | 0.00566 | 51 | 0.00523 | 59 |
| hsa00271 | Methionine metabolism | 11 | 0.6875 | 0.3158 | 0.00239 | 0.00001452 | 4 | 0.00044 | 7 | 0.00239 | 59.5 |
| hsa00260 | Glycine, serine and threonine metabolism | 16 | 0.3556 | 0.1391 | 0.00168 | 0.00000594 | 6 | 0.00153 | 8 | 0.00082 | 61.5 |
| hsa00330 | Arginine and proline metabolism | 21 | 0.3448 | 0.2075 | 0.00207 | 0.00001056 | 10 | 0.00223 | 14 | 0.00388 | 64 |
| hsa04512 | ECM-receptor interaction | 31 | 0.3563 | 0.0909 | 0.00076 | 0.00000023 | 2 | 0.00010 | 5 | 0.00058 | 71.5 |
| hsa00280 | Valine, leucine and isoleucine degradation | 19 | 0.3519 | 0.3913 | 0.00636 | 0.00002807 | 10 | 0.00657 | 14 | 0.00760 | 72 |
| hsa00310 | Lysine degradation | 18 | 0.3462 | 0.4231 | 0.00453 | 0.00000841 | 5 | 0.01567 | 5 | 0.00035 | 82 |
| hsa00100 | Biosynthesis of steroids | 8 | 0.4444 | 0.3902 | 0.00754 | 0.00006827 | 9 | 0.00769 | 9 | 0.00769 | 87 |
| hsa04670 | Leukocyte transendothelial migration | 31 | 0.2650 | 0.0656 | 0.00135 | 0.00000028 | 2 | 0.00007 | 3 | 0.00030 | 87.5 |
| hsa04910 | Insulin signaling pathway | 41 | 0.3037 | 0.1647 | 0.00713 | 0.00001028 | 8 | 0.00535 | 9 | 0.00583 | 89.5 |
| hsa00380 | Tryptophan metabolism | 30 | 0.3488 | 0.2289 | 0.00850 | 0.00006979 | 6 | 0.00455 | 7 | 0.00543 | 100 |
| hsa00130 | Ubiquinone biosynthesis | 7 | 0.4667 | 0.2500 | 0.00672 | 0.00003048 | 2 | 0.00552 | 2 | 0.00552 | 100 |
| hsa00564 | Glycerophospholipid metabolism | 19 | 0.2468 | 0.2464 | 0.00692 | 0.00005076 | 7 | 0.00742 | 10 | 0.00786 | 103.5 |
| hsa00020 | Citrate cycle (TCA cycle) | 14 | 0.4643 | 0.1121 | 0.00959 | 0.00006191 | 7 | 0.00758 | 7 | 0.00758 | 105 |
| hsa00650 | Butanoate metabolism | 20 | 0.4545 | 0.2326 | 0.00713 | 0.00007358 | 6 | 0.00977 | 6 | 0.00977 | 108 |
| hsa04514 | Cell adhesion molecules (CAMs) | 36 | 0.2727 | 0.1565 | 0.00305 | 0.00009319 | 2 | 0.00195 | 2 | 0.00195 | 112 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 13 | 0.2826 | 0.1200 | 0.00513 | 0.00012724 | 3 | 0.00875 | 3 | 0.00875 | 135.5 |
| hsa00500 | Starch and sucrose metabolism | 23 | 0.2949 | 0.1250 | 0.00955 | 0.00018004 | 5 | 0.01366 | 6 | 0.01538 | 141.5 |
| hsa00625 | Tetrachloroethene degradation | 4 | 0.4444 | 0.1250 | 0.02087 | 0.00043538 | 2 | 0.02087 | 2 | 0.02087 | 149 |
| hsa00970 | Aminoacyl-tRNA biosynthesis | 12 | 0.3750 | 0.0476 | 0.00654 | 0.00077841 | 2 | 0.02790 | 2 | 0.02790 | 154 |
| hsa00040 | Pentose and glucuronate interconversions | 6 | 0.2500 | 0.0588 | 0.00915 | 0.00050551 | 2 | 0.02248 | 2 | 0.02248 | 171 |
Gene names, gene descriptions, and significance analysis results of mapped genes in focal adhesion pathway obtained via SAM analysis, where “[ ]” showed upregulated (+) or downregulated (−) by rCFES treatment at q-value <5%.
| No. | Gene | Gene Description | |
|---|---|---|---|
| 1 | SHC3 | SHC transforming protein 3 | 0.0000 [+] |
| 2 | ACTN2 | Actinin, alpha 2 | 0.0068 [+] |
| 3 | BIRC3 | Baculoviral IAP repeat-containing 3 | 0.0211 [+] |
| 4 | SPP1 | Secreted phosphoprotein 1 | 0.0211 [+] |
| 5 | AF086032 | Protein phosphatase 1, regulatory (inhibitor) subunit 12A | 0.0278 [+] |
| 6 | KDR | Kinase insert domain receptor | 0.0278 [+] |
| 7 | DDI1 | DDI1, DNA-damage inducible 1,homolog 1 (S. cerevisiae) | 0.0278 [+] |
| 8 | ACTB | Actin, beta | 0.0000 [−] |
| 9 | FLNA | Filamin A, alpha (actin binding protein 280) | 0.0000 [−] |
| 10 | ACTG1 | Actin, gamma 1 | 0.0000 [−] |
| 11 | CAV1 | Caveolin 1, caveolae protein, 22kDa | 0.0000 [−] |
| 12 | ITGB1 | Integrin, beta 1 | 0.0000 [−] |
| 13 | ITGA6 | Integrin, alpha 6 | 0.0000 [−] |
| 14 | COL1A2 | Collagen, type I, alpha 2 | 0.0000 [−] |
| 15 | CAPN2 | Calpain 2, (m/II) large subunit | 0.0000 [−] |
| 16 | AKT1 | V-akt murine thymoma viral oncogene homolog 1 | 0.0010 [−] |
| 17 | TNXB | Tenascin XB | 0.0010 [−] |
| 18 | ITGA5 | Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) | 0.0010 [−] |
| 19 | RAPGEF1 | Rap guanine nucleotide exchange factor (GEF) 1 | 0.0014 [−] |
| 20 | ITGA8 | Integrin, alpha 8 | 0.0014 [−] |
| 21 | ITGA4 | Integrin, alpha 4 | 0.0014 [−] |
| 22 | PIK3R3 | Phosphoinositide-3-kinase,regulatory subunit 3 (p55, gamma) | 0.0014 [−] |
| 23 | FN1 | Fibronectin 1 | 0.0014 [−] |
| 24 | LAMA4 | Laminin, alpha 4 | 0.0016 [−] |
| 25 | THBS1 | Thrombospondin 1 | 0.0016 [−] |
| 26 | IGF1R | Insulin-like growth factor 1 receptor | 0.0016 [−] |
| 27 | COL1A1 | Collagen, type I, alpha 1 | 0.0016 [−] |
| 28 | CCND1 | Cyclin D1 | 0.0016 [−] |
| 29 | MET | Met proto-oncogene (hepatocyte growth factor receptor) | 0.0016 [−] |
| 30 | ACTN4 | Actinin, alpha 4 | 0.0019 [−] |
| 31 | AK025363 | Parvin, alpha | 0.0019 [−] |
| 32 | AKT2 | V-akt murine thymoma viral oncogene homolog 2 | 0.0019 [−] |
| 33 | CAV2 | Caveolin 2 | 0.0027 [−] |
| 34 | VCL | Vinculin | 0.0027 [−] |
| 35 | ZYX | Zyxin | 0.0027 [−] |
| 36 | TNC | Tenascin C (hexabrachion) | 0.0027 [−] |
| 37 | ACTN3 | Actinin, alpha 3 | 0.0028 [−] |
| 38 | VASP | Vasodilator-stimulated phosphoprotein | 0.0028 [−] |
| 39 | COL5A1 | Collagen, type V, alpha 1 | 0.0028 [−] |
| 40 | VEGFC | Vascular endothelial growth factor C | 0.0039 [−] |
| 41 | FAK | Focal adhesion kinase | 0.0047 [−] |
| 42 | PARVB | Parvin, beta | 0.0047 [−] |
| 43 | COL4A6 | Collagen, type IV, alpha 6 | 0.0047 [−] |
| 44 | LAMA5 | Laminin, alpha 5 | 0.0068 [−] |
| 45 | MAPK1 | Mitogen-activated protein kinase 1 | 0.0088 [−] |
| 46 | AK025363 | Parvin, alpha | 0.0019 [−] |
| 47 | THBS4 | Thrombospondin 4 | 0.0116 [−] |
| 48 | ERBB2 | V-erb-b2 erythroblastic leukemiaviral oncogene homolog 2 | 0.0157 [−] |
| 49 | AF207599 | Homo sapiens pRb-interacting protein RbBP-36 mRNA | 0.0157 [−] |
| 50 | DOCK1 | Dedicator of cytokinesis 1 | 0.0157 [−] |
| 51 | COL5A2 | Collagen, type V, alpha 2 | 0.0211 [−] |
| 52 | PIK3R5 | Phosphoinositide-3-kinase, regulatory subunit 5, p101 | 0.0211 [−] |
| 53 | ITGAV | Integrin, alpha V | 0.0211 [−] |
| 54 | LAMA2 | Laminin, alpha 2 | 0.0278 [−] |
| 55 | ARHGAP5 | Rho GTPase activating protein 5 | 0.0278 [−] |
| 56 | VAV2 | Vav 2 oncogene | 0.0278 [−] |
| 57 | CAV3 | Caveolin 3 | 0.0278 [−] |
| 58 | BCAR1 | Breast cancer anti-estrogen resistance 1 | 0.0369 [−] |
| 59 | EGFR | Epidermal growth factor receptor | 0.0369 [−] |
| 60 | MAPK9 | Mitogen-activated protein kinase 9 | 0.0369 [−] |
| 61 | AA599881 | Platelet-derived growth factor receptor, alpha polypeptide | 0.0474 [−] |
| 62 | THBS1 | Thrombospondin 1 | 0.0016 [−] |
| 63 | GRB2 | Growth factor receptor-bound protein 2 | 0.0474 [−] |
| 64 | LAMA3 | Laminin, alpha 3 | 0.0474 [−] |
| 65 | CRKL | V-crk sarcoma virus CT10 oncogene homolog (avian)-like | 0.0474 [−] |
Figure 3Functional analysis of the 65 important genes in the focal adhesion pathway using GOstat, in which five GO terms were identified to best describe the functional disorders associated with these 65 important genes, including developmental process, cell motility, localization of cell, biological adhesion, and cell adhesion.
Figure 4Validation of microarray data by qRT-PCR analysis for 5 genes: (a) LAMA4, (b) ITGB1, (c) PIK3R3, (d) BIRC3, and (e) NFKBIA. The data are expressed as mean values (± standard deviation) of three experiments.
Figure 5Inferred model for the rCFES-regulated focal adhesion pathway in WI-38 cells. LAMA4, PIK3R3, BIRC3, and NFKBIA identified in this study were included in the rCFES-regulated model in WI-38 cells. Upregulated genes were marked by “↑” and downregulated genes by “⊥”. Dotted arrows were links requiring further confirmation and the numbers in “[ ]” were the supportive previous works listed in the reference.